LogicBio Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq:LOGC), a clinical-stage genetic medicine company, announced that CEO Frederic Chereau will present at two upcoming investor conferences. He will present at the Barclays Global Healthcare Conference on March 11, 2021, at 4:10 p.m. ET. Additionally, he will record a presentation for the H.C. Wainwright Global Life Sciences Conference, available online from March 9-10, 2021. LogicBio focuses on innovative gene delivery and editing platforms to treat rare diseases, utilizing the GeneRide and sAAVy platforms for effective gene therapy development.

LEXINGTON, Mass., Feb. 26, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be presenting an overview of the company at upcoming investor conferences.

• Mr. Chereau will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 4:10 p.m. ET. A link to the Barclays presentation will be available under the "Events and Presentations" section of LogicBio's website, found here: https://investor.logicbio.com/events-and-presentations/events.
• Mr. Chereau will also record a presentation for the H.C. Wainwright Global Life Sciences Conference, which will be available on the H.C Wainwright website for the duration of the conference, March 9-10, 2021.

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide^TM platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy^TM capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit https://www.logicbio.com/.

Media Contacts:

Adam Daley
Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
adaley@berrypr.com

Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com 

Investor Contacts:

Matt Lane
Gilmartin Group
617-901-7698
matt@gilmartinir.com  

View original content:http://www.prnewswire.com/news-releases/logicbio-therapeutics-to-present-at-upcoming-investor-conferences-301236663.html

SOURCE LogicBio Therapeutics, Inc.

FAQ

When will LogicBio Therapeutics present at the Barclays Global Healthcare Conference?

LogicBio Therapeutics will present at the Barclays Global Healthcare Conference on March 11, 2021, at 4:10 p.m. ET.

Where can I watch the presentation by LogicBio's CEO?

The presentation by LogicBio's CEO can be watched through the 'Events and Presentations' section on LogicBio's website.

What is the focus of LogicBio Therapeutics?

LogicBio Therapeutics focuses on pioneering gene delivery and editing platforms to address rare and serious diseases.

When will the H.C. Wainwright Global Life Sciences Conference take place?

The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021.

What are the key platforms used by LogicBio Therapeutics?

LogicBio Therapeutics utilizes GeneRide and sAAVy platforms for gene therapy development.